@n1.Aminos Memes. Jokes. Pop culture references. Dramatic overreactions for entertainment purposes only. We discuss science. We laugh at oversimplifications. We do not give medical advice. If you detect sarcasm… good. If you detect humor… excellent. If you’re reporting memes… maybe touch some grass and get over it.

We just completed a full rebuild of Stack Tracker. This isn’t a cosmetic update. It’s a new infrastructure layer for people who build, track, and publish stacks. We’re opening two lanes right now: 1️⃣ 2-Week Soft Launch (User Testers) 2️⃣ Creator + WellnessPro Early Access If you track supplements, peptides, protocols, or coach clients — this may be relevant. 🧪 1️⃣ 2-WEEK SOFT LAUNCH — STRUCTURED TESTING WINDOW The new build is live. Now we need real users to: • Pressure test performance • Catch bugs or friction • Validate onboarding • Confirm integrations behave properly • Tighten small UX details This isn’t a rough beta. It’s polished — we just want it airtight before scale. 💎 EARLY ADVANTAGE If you join during this window and stay: • You lock in best pricing • No future tier jumps • No surprise increases If you’ve ever wanted to shape a platform before it grows — this is that moment. Comment “IN” after you submit so we know to watch for you. 🧠 2️⃣ CREATOR + WELLNESSPRO EARLY ACCESS This is where it gets interesting. Stack Tracker 2.0 isn’t just a tracking app. It’s becoming a distribution + monetization engine for stack builders and educators. If you are a: • Creator • Influencer • Coach • Wellness Professional • Lab reviewer • Biohacker educator You’ll soon be able to: 🔹 Publish Structured Protocols Make them: • Free to import • Preview-only with paid unlock • Fully monetized digital stacks No PDFs. No messy Google Docs. No screenshots. Structured. Importable. Clean. 🔹 Build an In-App Profile • Add website + socials • Build followers • Notify them when new stacks drop • Offer exclusive paid content Owned distribution — inside intent. 🔹 Monetize Directly (WellnessPros) • Paid protocol reviews • Lab + wearable data review • Monthly coaching • Promotions + discounts • Paywalled stacks After 30 days with a client, engagement continues without added platform friction. You scale. The system scales with you. 🔹 Get Discovered Inside Stack Tracker users will see:

They said it was risky. They said it was illegal. They said it was counterfeit, contaminated, reckless, life-threatening. Now? They’re preparing to patent it, brand it, and call it revolutionary. 🧬 The Data They’re Celebrating Eli Lilly’s Phase 3 TRIUMPH-4 data on retatrutide shows: 📉 28.7% average body-weight reduction at 68 weeks (12 mg dose) 🦵 Significant reduction in knee pain (WOMAC improvements) ❤️ Improvements in triglycerides, non-HDL cholesterol, hs-CRP, and systolic BP 🔥 ~23–24% of participants lost ≥35% body weight (bariatric-range outcomes) That’s not incremental. That’s surgical territory. And yes, tolerability issues were there: Nausea ~38–43% Diarrhea ~33–35% Vomiting ~20% Discontinuation rates up to ~18% New signal: dysesthesia Some participants reportedly stopped because they lost too much weight. Let that sink in. ⚖️ Now Remember the Messaging From Not Long Ago… Before commercial approval was realistic, the narrative was very different. The tone was: “Unapproved GLP-1 products are dangerous.” “Compounded versions cause hospitalizations.” “Research-use ingredients are illegal and harmful.” “Online sales = counterfeit, contamination, overdoses.” Regulators and corporate PR leaned heavily into: Counterfeit scare language Hospitalization statistics Cease-and-desist campaigns Litigation against telehealth and compounders Anything outside the branded channel? Framed as reckless. Even retatrutide as an API was explicitly warned against in FDA communications. The emotional positioning was clear: If it’s not ours, it’s unsafe. 🔄 And Now? Now the same molecule is being positioned as: Historic Breakthrough Bariatric-level Cardiometabolically transformative Soon it will likely be: Patented Exclusively distributed Marketed as the future of obesity treatment “Well tolerated and effective when used appropriately” Same compound. Different control. 🧠 The Pattern This isn’t about denying safety concerns. Large-scale human data matters.